Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. News
Syros Pharmaceuticals, Inc. Quantitative Score
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals, Inc. Earnings & Revenue
Syros Pharmaceuticals, Inc. Financials
Table Compare
Compare SYRS metrics with: | |||
|---|---|---|---|
Earnings & Growth | SYRS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SYRS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SYRS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SYRS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Syros Pharmaceuticals, Inc. Income
Syros Pharmaceuticals, Inc. Balance Sheet
Syros Pharmaceuticals, Inc. Cash Flow
Syros Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Syros Pharmaceuticals, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Syros Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Dr. James E. Bradner M.D. | Founder |
| Matthew Foster | Chief Restructuring Officer |
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. James E. Bradner M.D. | Founder | 1972 | -- | |
| Matthew Foster | Chief Restructuring Officer | -- | ||
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder & Member of Scientific Advisory Board | -- |
Syros Pharmaceuticals, Inc. Insider Trades
| Date | 2 Dec |
| Name | Simonian Nancy A |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 37070 |
| Date | 25 Nov |
| Name | Simonian Nancy A |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 134713 |
| Date | 18 Nov |
| Name | Stephens Kristin |
| Role | Chief Development Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 36133 |
| Date | 18 Nov |
| Name | Roth David |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 12099 |
| Date | 19 Nov |
| Name | Quirk Gerald E |
| Role | Chief Legal & Compliance Offic |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 46657 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Dec | Simonian Nancy A | Director | Disposed | S-Sale | 37070 |
| 25 Nov | Simonian Nancy A | Director | Disposed | S-Sale | 134713 |
| 18 Nov | Stephens Kristin | Chief Development Officer | Disposed | S-Sale | 36133 |
| 18 Nov | Roth David | Chief Medical Officer | Disposed | S-Sale | 12099 |
| 19 Nov | Quirk Gerald E | Chief Legal & Compliance Offic | Disposed | S-Sale | 46657 |